((lp0
VisWord
p1
aVcase
p2
aVstops
p3
aVstem
p4
accopy_reg
_reconstructor
p5
(cnltk.probability
FreqDist
p6
c__builtin__
dict
p7
(dp8
S'acute coronary syndrom'
p9
I16
sS'inpatient initiation of'
p10
I1
sS'coronary diseas'
p11
I8
sS'statins for'
p12
I1
sS'abbreviations hmg coa'
p13
I1
sS'restenosi'
p14
I1
sS'lipid-lowing therapi'
p15
I1
sS'fear'
p16
I1
sS'discharg'
p17
I2
sS'efficacy endpoint'
p18
I2
sS'evidence of ischemia'
p19
I2
sS'cohort studi'
p20
I1
sS'theoretical fear'
p21
I1
sS'placebo-controlled tri'
p22
I1
sS'coronary ev'
p23
I2
sS'non-q wave myocardial infarct'
p24
I1
sS'comparative efficaci'
p25
I1
sS'serious harm'
p26
I1
sS'dl'
p27
I4
sS'randomized placebo-controlled tri'
p28
I1
sS'risk'
p29
I5
sS'index hospit'
p30
I1
sS'arrhythmia'
p31
I1
sS'quantif'
p32
I1
sS'util'
p33
I1
sS'heart association guidelin'
p34
I1
sS'for the secondary prevent'
p35
I1
sS'treatment strategi'
p36
I1
sS'future secondary prevention studi'
p37
I1
sS'high dens'
p38
I1
sS'atorvastatin evalu'
p39
I2
sS'non-fatal myocardial infarct'
p40
I2
sS'cholesterol'
p41
I9
sS'prevent'
p42
I2
sS'revascular'
p43
I8
sS'natur'
p44
I1
sS'density lipoprotein'
p45
I4
sS'diseas'
p46
I8
sS'primary endpoint ev'
p47
I1
sS'concern'
p48
I1
sS'lipid-lowering therapi'
p49
I6
sS'randomized tri'
p50
I1
sS'secondary endpoints included strok'
p51
I1
sS'abbrevi'
p52
I1
sS'cardiolog'
p53
I1
sS'lowering therapi'
p54
I1
sS'evidence of'
p55
I1
sS'incremental clinical benefit'
p56
I1
sS'inpatient initiation of lipid-lowing therapi'
p57
I1
sS'secondary prevention studi'
p58
I1
sS'liver transaminase elev'
p59
I1
sS'secondary prevention statin tri'
p60
I1
sS'cardiovascular death'
p61
I1
sS'association guidelin'
p62
I1
sS'initiation of lipid-lowing therapi'
p63
I1
sS'hospital discharg'
p64
I2
sS'secondary prevention statin'
p65
I1
sS'coa'
p66
I1
sS'non-fatal strok'
p67
I1
sS'high-dose statin therapi'
p68
I1
sS'non-q wav'
p69
I1
sS'studi'
p70
I6
sS'baselin'
p71
I2
sS'incremental benefit'
p72
I3
sS'ci'
p73
I1
sS'miracl tri'
p74
I1
sS'guidelin'
p75
I1
sS'american heart association guidelin'
p76
I1
sS'q-wave'
p77
I1
sS'confidence interv'
p78
I3
sS'zocor'
p79
I2
sS'secondary endpoint'
p80
I1
sS'electrocardiogram'
p81
I1
sS'cholesterol target'
p82
I1
sS'aggress'
p83
I2
sS'admission ldl'
p84
I1
sS'relative risk'
p85
I2
sS'high density lipoprotein'
p86
I1
sS'myocardial infarct'
p87
I13
sS'prevention tri'
p88
I1
sS'systolic dysfunct'
p89
I1
sS'criteria'
p90
I1
sS'benefit conf'
p91
I1
sS'ischemia'
p92
I4
sS'strategi'
p93
I2
sS'endpoints included strok'
p94
I1
sS'inpatient initi'
p95
I1
sS'rehospitalization for'
p96
I1
sS'lipoprotein'
p97
I4
sS'liver'
p98
I1
sS'efficaci'
p99
I1
sS'hmg'
p100
I1
sS'generaliz'
p101
I1
sS'mg'
p102
I4
sS'endpoint'
p103
I8
sS'future secondary prevent'
p104
I1
sS'incremental benefit of combination therapi'
p105
I1
sS'q-wave myocardial infarct'
p106
I3
sS'of lipid-lowing therapi'
p107
I1
sS'clinical ev'
p108
I1
sS'hdl'
p109
I4
sS'heart'
p110
I4
sS'non-q wave myocardi'
p111
I1
sS'ptca'
p112
I2
sS'secondary prevention tri'
p113
I1
sS'normal occur'
p114
I1
sS'stroke'
p115
I2
sS'atorvastatin'
p116
I9
sS'coronary revascular'
p117
I7
sS'occur'
p118
I1
sS'contribut'
p119
I1
sS'trial'
p120
I7
sS'for symptomatic myocardial ischemia'
p121
I1
sS'coronari'
p122
I1
sS'evid'
p123
I1
sS'myocardi'
p124
I2
sS'prognost'
p125
I1
sS'primary endpoint'
p126
I1
sS'clinical benefit'
p127
I7
sS'ascertain'
p128
I1
sS'cardiac death'
p129
I3
sS'aforementioned cohort studi'
p130
I1
sS'in-hospital initiation of lipid-lowering therapi'
p131
I1
sS'atorvastatin treat'
p132
I1
sS'ventricular systolic dysfunct'
p133
I1
sS'percutan'
p134
I1
sS'acute coronari'
p135
I1
sS'elev'
p136
I1
sS'exclus'
p137
I1
sS'non-q-wave myocardial infarct'
p138
I2
sS'randomized placebo-controlled clinical tri'
p139
I1
sS'advisory board member for pf'
p140
I1
sS'simvastatin daili'
p141
I2
sS'infection therapi'
p142
I2
sS'primary efficacy endpoint'
p143
I2
sS'ldl'
p144
I5
sS'advisory board member for'
p145
I1
sS'death'
p146
I4
sS'vascular smooth muscle cell prolifer'
p147
I1
sS'non-pharmacologic lipid-lowering intervent'
p148
I1
sS'of simvastatin daili'
p149
I2
sS'rehospitalization for symptomatic myocardi'
p150
I1
sS'coronary syndrom'
p151
I17
sS'dysfunct'
p152
I1
sS'treatment'
p153
I3
sS'densiti'
p154
I3
sS'secondary endpoints includ'
p155
I1
sS'therapi'
p156
I20
sS'theoretical concern'
p157
I1
sS'lipid-lowering intervent'
p158
I1
sS'placebo-controlled clinical tri'
p159
I1
sS'symptomatic myocardial ischemia'
p160
I2
sS'of lipid-lowering therapi'
p161
I1
sS'invasive strategi'
p162
I1
sS'health car'
p163
I1
sS'in-hospital initiation of'
p164
I1
sS'accru'
p165
I1
sS'benefit'
p166
I8
sS'intervent'
p167
I1
sS'confid'
p168
I3
sS'atorvastatin-treated pati'
p169
I1
sS'harm'
p170
I1
sS'of combination therapi'
p171
I1
sS'aggressive treatment strategi'
p172
I1
sS'interv'
p173
I3
sS'liver transaminas'
p174
I1
sS'cabg'
p175
I2
sS'statin tri'
p176
I1
sS'vascular smooth muscle cel'
p177
I1
sS'statin'
p178
I6
sS'aggressive cholesterol'
p179
I2
sS'event'
p180
I8
sS'syndrom'
p181
I17
sS'admission ldl cholesterol'
p182
I1
sS'admiss'
p183
I4
sS'infarct'
p184
I13
sS'confirm'
p185
I1
sS'mg of simvastatin daili'
p186
I2
sS'pravastatin'
p187
I2
sS'endpoint ev'
p188
I1
sS'health'
p189
I1
sS'surgical coronary revascular'
p190
I1
sS'complic'
p191
I2
sS'caucasian'
p192
I1
sS'ecg'
p193
I2
sS'investig'
p194
I1
sS'patient'
p195
I3
sS'primary composite endpoint'
p196
I1
sS'cell prolifer'
p197
I1
sS'prevention studi'
p198
I1
sS'confer'
p199
I1
sS'vascular smooth muscl'
p200
I1
sS'safety endpoint'
p201
I1
sS'wave myocardial infarct'
p202
I1
sS'in-hospital initi'
p203
I1
sS'pfizer'
p204
I1
sS'hdl cholesterol'
p205
I1
sS'rehospit'
p206
I4
sS'cardiovascular ev'
p207
I2
sS'advisory board'
p208
I1
sS'ldl cholesterol'
p209
I3
sS'miracl'
p210
I9
sS'smooth muscle cell prolifer'
p211
I1
sS'heart protect'
p212
I1
sS'incremental benefit conf'
p213
I1
sS'lipid lowering therapi'
p214
I1
sS'serum cholesterol'
p215
I1
sS'total cholesterol'
p216
I1
sS'ventricular arrhythmia'
p217
I1
sS'for pfiz'
p218
I2
sS'atorvastatin-tr'
p219
I1
sS'of ischemia'
p220
I1
sS'board member for pf'
p221
I1
sS'statins for the secondary prevent'
p222
I1
sS'baseline cholesterol'
p223
I1
sS'daili'
p224
I2
sS'statin therapi'
p225
I8
sS'trial safety endpoint'
p226
I1
sS'abbreviations hmg'
p227
I1
sS'clinical trial safety endpoint'
p228
I1
sS'prevention statin tri'
p229
I1
sS'heart protection studi'
p230
I1
sS'aggrastat'
p231
I2
sS'the secondary prevent'
p232
I1
sS'pharmacolog'
p233
I1
sS'exclusion criteria'
p234
I1
sS'target'
p235
I1
sS'statins for th'
p236
I1
sS'observational studi'
p237
I1
sS'baseline lipid'
p238
I2
sS'mg of'
p239
I2
sS'a-2-z studi'
p240
I1
sS'risk pati'
p241
I2
sS'ac'
p242
I2
sS'included strok'
p243
I1
sS'evalu'
p244
I2
sS'rehospitalization for symptomatic myocardial ischemia'
p245
I1
sS'cardiac ev'
p246
I1
sS'initiation of lipid-lowering therapi'
p247
I1
sS'hospit'
p248
I4
sS'hmg coa'
p249
I1
sS'clinical trial safeti'
p250
I1
sS'clinical tri'
p251
I2
sS'infect'
p252
I2
sS'simvastatin'
p253
I2
sS'risk natur'
p254
I1
sS'index'
p255
I1
sS'aggressive treat'
p256
I1
sS'prolifer'
p257
I1
sS'electrocardiographic q-wav'
p258
I1
sS'transaminase elev'
p259
I1
sS'a-2-z'
p260
I2
sS'muscle cell prolifer'
p261
I1
sS'benefit of combination therapi'
p262
I1
sS'rr'
p263
I5
sS'rehospitalization for symptomat'
p264
I1
sS'protection studi'
p265
I1
sS'myocardial ischemia'
p266
I5
sS'rr relative risk'
p267
I1
sS'secondary prevent'
p268
I5
sS'ischemic ev'
p269
I1
sS'incremental benefit of'
p270
I1
stp271
Rp272
(dp273
S'_N'
p274
I572
sS'_max_cache'
p275
NsS'_item_cache'
p276
NsS'_Nr_cache'
p277
Nsbtp278
.